- Corona-risk factors: Researchers discover new ones Biomarker
- Protein should severe illness to predict
- It is the deciding factor Protein concentration
- Insights could Immunotherapy enable
Some people who become infected with the coronavirus notice almost nothing. Others become seriously ill and must be hospitalized. on Risk factors Even today – a year after the global outbreak of the Covid 19 pandemic – there is still no absolute clarity. Researchers from Erlangen they now have references to one Biomarker discovered, from Anticipate serious disease progression and may even provide therapy.
One thing is for now: older people are more likely to get seriously ill than Covid-19. Other factors, such as smoking, increase the risk of serious illness. Obesity can also favor serious progress.
However, there is still no agreement on mechanisms that increase the risk of severe coronary heart disease. And again and again people get seriously ill who don’t actually belong to any risk group.
The course of coronary heart disease: protein concentration should allow for prediction
Two doctors from Erlangen – Dr. Georg Weber, Deputy Director of the Clinic and Senior Physician at the Surgical Clinic of the University Clinic Erlangen, and Dr. Alan Bnard, an employee at a surgical clinic – now raises hopes for improved identification of a serious illness. Therapy is even possible.
Together with other researchers from the working group “Cellular immunity in inflammation and cancer” at the University Hospital Erlangen, the two have an important question Frhindikator to find out if the viral infection will be mild or severe: Immunbotenstoff Interleukin-3. The results of the study were published in the journal Nature Communications.
Interleukin-3 is a Proteinwhich is stimulates the natural immune defenses of humans. It stimulates the process of blood formation and is therefore used, for example, after bone marrow transplantation, general anemia or after chemotherapy to stimulate blood formation.
Weber and Bnard in the study now showed that a low levels of interleukin-3 in blood plasma often with severe course of Covid-19 disease goes hand in hand. Interleukin-3 plays a major role in organizing the body’s immune response. At the site of inflammation – for example, pneumonia caused by SARS-Cov-2 – it stimulates cells there to produce the protein CXCL12.
Immunotherapy: A new method of treatment could protect the lungs from coronavirus infection
“This protein interacts with plasmacytoid dendritic cells – non-specific immune cells that normally circulate in the bloodstream. CXCL12 lures them to some extent into inflamed lungs, where they curb the replication of the virus that causes them, ”explains Dr. Weber. In other words: Interleukin-3 indirectly indirectly improves the body’s immune defenses and focuses it.
Interleukin-3 levels can therefore provide an important clue to a difficult course. Until now, this assessment could only be based on far more rough criteria – such as age or certain previous illnesses.
“But people who don’t belong to any risk group may also have little interleukin-3 in their blood. With this, the difficult course so far has surprised and adequate medical care may be too late “, says Dr. Weber for consideration.
Now, based on the results of the study, important decisions could be made about treating patients with Covid-19 at an earlier time. Even more: in perspective, it is conceivable develop immunotherapy, in which interleukin-3 is used in the form of an inhaler to precisely protect the lungs from virus infection.